logo
Plus   Neg
Share
Email

Abbott To Present Phase2 Result From InterferonFree Studies For Treatment Of HCV

Abbott Laboratories (ABT) said that it will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C or HCV at the International Liver Congress 2012 or ILC 2012, the annual meeting of the European Association for the Study of the Liver or EASL, April 18-22 in Barcelona, Spain.

In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment or SVR12 in 95 percent and 93 percent of treatment-naive genotype 1 or GT1 patients.

In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r. In addition, SVR12 was achieved in 47 percent of patients who were previous non-responders to past HCV treatment, the company said.

In a separate study, known as "Pilot," 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks or SVR24, Abbott noted.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Tens of thousands of casino workers in Las Vegas voted Tuesday to authorize a city-wide strike anytime after June 1 if labor contract agreements are not reached before they expire at the end of May. This would be the first strike in more than three decades in Las Vegas and could cripple the city's famed hospitality industry. Ten former and current employees of McDonald's Corp. have filed sexual harassment complaints with the federal government against the fast food giant. The women filed the complaints with the U.S. Equal Employment Opportunity Commission or EEOC and are receiving support from Fight for $15, which is organizing the effort. The TIME's UP Legal Defense Fund is covering legal fees for the women. A bill rolling back financial regulations implemented following the 2008 financial crisis is headed to President Donald Trump's desk for his signature after being approved by the House on Tuesday. The House voted 258 to 159 in favor of the Economic Growth, Regulatory Relief, and Consumer Protection...
Follow RTT